Plain-English translation of NCT06133374 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Researchers are testing a new molecular test called Thyroid GuidePx that helps doctors understand how aggressive someone's papillary thyroid cancer is. The goal is to see whether this test works equally well on small tissue samples taken before surgery (which would help doctors plan the best surgery) as it does on larger samples taken during surgery. This could help doctors make better treatment decisions earlier on.
Currently, doctors can't know how aggressive a thyroid cancer is until after surgery when they have the full tumor to examine. The new test could provide this critical information before surgery, allowing doctors to plan the most appropriate surgical approach for each patient.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will have a fine needle biopsy (a small tissue sample taken with a thin needle) that will be tested with the new Thyroid GuidePx test. You will then proceed with your planned thyroid surgery, and tissue removed during surgery will also be tested. Researchers will compare the results from both samples to see if the smaller biopsy sample gives the same information as the larger surgical sample.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
Canada
Sponsor
University of Calgary
Collaborators
Qualisure Diagnostics Inc., Alberta Health services
Enrollment target
~130 participants
Started
July 2024
Primary completion
May 2028
Age range
18 Years and older
Last updated on clinicaltrials.gov in January 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Elleine Allapitan
Alberta Health services
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.